Form 4: Lineage Cell Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Deborah J Andrews, a director at Lineage Cell Therapeutics, acquired 75,000 stock options on July 1, 2024.
Summary
- On July 1, 2024, Deborah J Andrews, a director of Lineage Cell Therapeutics, acquired 75,000 stock options.
- The options have an exercise price of $0.9541.
- The options will vest and become exercisable on July 1, 2025, contingent upon the director's continued service with the company.
- The options expire on July 1, 2034.
- Following the transaction, Andrews directly owns 75,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's acquisition of stock options, which can be viewed as a slightly positive sign of confidence but doesn't provide substantial information to significantly alter sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Director acquired stock options. |
| 07/01/2025 | Vesting date of the stock options, subject to continued service. |
| 07/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.